• TRADE NAME: Keytruda (Merck Sharpe & Dohme)
• INDICATIONS: Unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor
  
• SYNONYM: Lambrolizumab
• CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Immune checkpoint inhibitor (incl. programmed death receptor-1 (PD-1) inhibitor), Monoclonal antibody
• HALF-LIFE: 26 days

• FDA APPROVAL DATE: 09/04/2014
• CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
  None known

• See adverse reactions attributed to class:

  Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)

  Immune checkpoint inhibitor (incl. programmed death receptor-1 (PD-1) inhibitor)

  Monoclonal antibody

DRUG REVIEW ARTICLE

DRUG REVIEW ARTICLE #2

Click on the DRUG REVIEW ARTICLE links (above) to see two reviews of pembrolizumab in the Taylor & Francis journal Expert Opinion on Drug Safety.

(Note that non-subscribers to the journal will only be able to see an abstract of the article.)